Rakuten Trade Research Reports
Technical View - Cengild Medical Berhad
rakutentrade
Publish date: Thu, 04 Aug 2022, 11:30 AM
rakutentrade
0 2,152
An official blog in I3investor to publish research reports provided by Rakuten Trade research team.
All materials published here are prepared by Rakuten Trade. For latest offers on Rakuten Trade products and news, please refer to: https://www.rakutentrade.my/
To sign up for an account: http://bit.ly/40BNqKI
Rakuten Trade
Hotline: +603 2110 7110 (Account Opening, General enquiry)
Email: customerservice@rakutentrade.my
All materials published here are prepared by Rakuten Trade. For latest offers on Rakuten Trade products and news, please refer to: https://www.rakutentrade.my/
To sign up for an account: http://bit.ly/40BNqKI
Rakuten Trade
Hotline: +603 2110 7110 (Account Opening, General enquiry)
Email: customerservice@rakutentrade.my
Cengild Medical Berhad (CENGILD, 0243)
• Share price closed 5.88% higher at RM0.45 on Wednesday.
• CENGILD is on an uptrend movement from its low of RM0.335 on 17 June. It is also trading above its upward sloping MA 20 line and pending breakout at its first resistance of RM0.465. Its MACD indicator is showing uptick momentum, therefore share price is expected to move higher.
• Resistance levels are identified at RM0.465 (R1) and RM0.48 (R2).
• On the flipside, support levels are pegged at RM0.41 (S1) and RM0.405 (S2).
Source: Rakuten Research - 4 Aug 2022
Related Stocks
| Chart | Stock Name | Last | Change | Volume |
|---|
Market Buzz
More articles on Rakuten Trade Research Reports
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
Latest Videos
MQ Trading Signals
Time
Signal
Duration
Type
2024-11-19 09:00:00
EMA 5
30 Mins
BUY
2024-11-19 08:00:00
ADX
Daily
BUY
Apps
Top Articles
1
5
BFM Podcast
6
BFM Podcast
8
BFM Podcast
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
